Concepedia

Lorraine A. Cazenave

LA

4

Publications

351

Citations

4

H-Index

1993

Active since

Affiliations

National Cancer Institute(Current)

The University of Texas MD Anderson Cancer Center

Lorraine A. Cazenave is an author at National Cancer Institute specializing in radiation oncology, surgery, and colorectal cancer.

Top concepts

Publications per year

1993–2000

4

Publications

4

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

HM Kantarjian, Miloslav Beran, Amy Ellis et al. · Blood · 1993 · 132 citations · Full text

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

HM Kantarjian, Miloslav Beran, Amy Ellis et al. · Blood · 1993 · 94 citations · Full text

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

Paula M. Fracasso, Peter Westerveldt, Carole A. Fears et al. · Journal of Clinical Oncology · 2000 · 82 citations

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer

Scott Wadler, Laura Tenteromano, Lorraine A. Cazenave et al. · Cancer Chemotherapy and Pharmacology · 1994 · 43 citations

, , +9

Rows per page

1–4 of 4